• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA kicks the can on off-label marketing

January 16, 2018 By Sarah Faulkner

FDAThe FDA has placed an indefinite hold on implementing new regulations relating to how the agency determines a medical product’s intended use.

The decision to press pause on the new rules drew cheers from the medical device and pharmaceutical industries, after companies voiced their concerns last year that the proposed changes were unclear.

The FDA’s new language on intended use was meant to update the types of evidence that the agency can use to decide how a manufacturer intended for patients and doctors to use its product.

“By having clear and consistent rules appropriately grounded in public health policy that address this and related issues, the FDA is better able to maintain vigorous oversight and take enforcement actions when necessary. We need more time to consider the feedback we received and to make sure that our approach is guided by our public health mandate and to ensure the clarity of our rules on the subject,” the FDA said in a statement.

“That’s why today we proposed to delay, until further notice, the effective date of those portions of the final rule that would have revised the FDA’s existing regulations describing the types of evidence that may be considered in determining a medical product’s intended uses.”

While the FDA reviews the comments that it received for the proposed policy changes, the agency said it will revert to its existing regulations to determine the intended use of medical products.

The FDA pointed out that the new language for intended use was part of a non-controversial final rule notice that clarified when tobacco products will be regulated as medical products. To ensure that the final rule goes into effect, the FDA has decoupled the intended use language from the new tobacco rule.

“We remain committed to rulemaking on the subject of intended use, and to an open and public process regarding the substance of the rule,” the agency added. “In order to allow time to review comments received on the proposal to delay the March 19, 2018 effective date of the portion of the rule that related to intended use, and to prepare and publish a final rule effectuating the proposed delay, the agency has opened a comment period that will remain open until February 5, 2018.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS